IRCCS Sacro Cuore Don Calabria di Negrar: Not applicable (device, behavioral) study in Strongyloides Stercoralis Infection, Device Performance (780 participants)
IRCCS Sacro Cuore Don Calabria di Negrar: Not applicable (device, behavioral) study in Strongyloides Stercoralis Infection, Device Performance (780 participants). Its enrollment of 780 is top-decile (93rd percentile of 8,879 records). Dated 21 days ago, it is in the active follow-up window. Score 30/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 780 · 93th percentile of 8,879 ClinicalTrialStartPulse records · 9.8x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | IRCCS Sacro Cuore Don Calabria di Negrar |
| Sponsor type | Academic and hospital |
| Study | Evaluation of the Rapid Diagnostic Test SsRT+ for Strongyloides Stercoralis |
| NCT ID | NCT07876622 |
| Phase | Not applicable (device, behavioral) |
| Status | active not recruiting |
| Conditions | Strongyloides Stercoralis Infection; Device Performance; Diagnostic |
| Intervention types | diagnostic test |
| Target enrollment | 780 |
| Site countries | Italy |
| Posted | 2026-10-15 |
| Planned start | 2026-10-02 |
| Event | Newly registered study |
| Event date | 2026-10-15 |
| enrollment percentile | 93th of 8,879 (median 80, 9.8x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch IRCCS Sacro Cuore Don Calabria di Negrar
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock IRCCS Sacro Cuore Don Calabria di Negrar + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-15
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: IRCCS Sacro Cuore Don Calabria di Negrar and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- IRCCS Sacro Cuore Don Calabria di Negrar's enrollment: 93rd percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
30 / 100 Score
- 780 participants planned.
What is the ClinicalTrialStartPulse record for IRCCS Sacro Cuore Don Calabria di Negrar?
IRCCS Sacro Cuore Don Calabria di Negrar registered a Not applicable (device, behavioral) study (NCT07876622) in Strongyloides Stercoralis Infection targeting 780 participants, posted 2026-10-15.
How does IRCCS Sacro Cuore Don Calabria di Negrar compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 780 is 9.8x the median of 80 across 8,879 records. It is 21 days old, still within a typical 45-day follow-up window. Its Score of 30/100 is modest; treat it as background rather than a priority.
IRCCS Sacro Cuore Don Calabria di Negrar vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| IRCCS Sacro Cuore Don Calabria di Negrar | NONUS | 780 | 93rd | 2026-10-15 |
| Galderma R&D | NONUS | 326 | 84th | 2026-11-02 |
| Galderma R&D | NONUS | 162 | 72nd | 2026-11-03 |
| A.M.I. Agency for Medical Innovations GmbH | NONUS | 100 | 60th | 2026-10-30 |
Related records
ClinicalTrialStartPulse: Not applicable (device, behavioral) ClinicalTrialStartPulse: Outside the US only
How to monitor IRCCS Sacro Cuore Don Calabria di Negrar and peer not applicable (device, behavioral) records
Get new ClinicalTrialStartPulse records like IRCCS Sacro Cuore Don Calabria di Negrar by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.